30–50 Dose as in normal renal function10–30 Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unlikely to be dialysed. Dose as in GFR <10 mL/min
CAV/VVHD      :Unlikely to be dialysed. Dose as in GFR=10–30 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Anticoagulants: may enhance effect of coumarins
Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis)
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
Administer preferably without food
OTHER INFORMATION
Increased amylase and lipase and hypophosphataemia are commonMost common side effects are diarrhoea and dermatological effectsSorafenib is metabolised primarily in the liver and undergoes oxidative metabolism mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in faeces, and 19% of the dose excreted in urine as glucuronidated metabolites. Unchanged sorafenib, accounting for 51% of the dose, was found in faeces but not in urine, indicating that biliary excretion of unchanged drug might contribute to the elimination of sorafenibA case report of interstitial nephritis has been reported in a patient with CRF due to FSGS.